FRANCESCHINI, Franco
 Distribuzione geografica
Continente #
NA - Nord America 12.513
EU - Europa 9.558
AS - Asia 5.419
SA - Sud America 692
AF - Africa 66
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 14
AN - Antartide 1
Totale 28.283
Nazione #
US - Stati Uniti d'America 12.403
IT - Italia 4.357
CN - Cina 1.938
SG - Singapore 1.663
UA - Ucraina 1.455
HK - Hong Kong 1.131
DE - Germania 1.045
BR - Brasile 635
FI - Finlandia 546
RU - Federazione Russa 397
GB - Regno Unito 379
IE - Irlanda 366
TR - Turchia 343
FR - Francia 325
PL - Polonia 158
SE - Svezia 106
IN - India 96
NL - Olanda 89
CA - Canada 72
AT - Austria 50
BE - Belgio 48
ES - Italia 33
BD - Bangladesh 27
CZ - Repubblica Ceca 27
EE - Estonia 24
IQ - Iraq 22
VN - Vietnam 19
MX - Messico 18
PK - Pakistan 18
RO - Romania 18
AR - Argentina 17
AU - Australia 17
CH - Svizzera 17
JP - Giappone 15
SA - Arabia Saudita 15
EG - Egitto 14
EU - Europa 14
HR - Croazia 14
ID - Indonesia 14
AE - Emirati Arabi Uniti 13
LT - Lituania 13
MA - Marocco 13
ZA - Sudafrica 13
AZ - Azerbaigian 12
IL - Israele 12
GR - Grecia 11
MK - Macedonia 11
VE - Venezuela 11
EC - Ecuador 10
IR - Iran 10
JO - Giordania 10
LU - Lussemburgo 10
SK - Slovacchia (Repubblica Slovacca) 10
KZ - Kazakistan 8
KG - Kirghizistan 7
PE - Perù 7
PH - Filippine 7
PT - Portogallo 7
UZ - Uzbekistan 7
AL - Albania 6
BG - Bulgaria 6
AM - Armenia 5
CI - Costa d'Avorio 5
CL - Cile 5
CR - Costa Rica 5
KE - Kenya 5
LV - Lettonia 5
NO - Norvegia 5
PA - Panama 5
RS - Serbia 5
TH - Thailandia 5
UG - Uganda 5
CY - Cipro 4
GE - Georgia 4
CO - Colombia 3
DK - Danimarca 3
DZ - Algeria 3
LI - Liechtenstein 3
MU - Mauritius 3
NZ - Nuova Zelanda 3
SI - Slovenia 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
BA - Bosnia-Erzegovina 2
ET - Etiopia 2
HN - Honduras 2
HU - Ungheria 2
KH - Cambogia 2
LK - Sri Lanka 2
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
KR - Corea 1
KW - Kuwait 1
LB - Libano 1
MD - Moldavia 1
Totale 28.272
Città #
Fairfield 1.572
Woodbridge 1.143
Hong Kong 1.129
Singapore 1.087
Jacksonville 1.085
Ashburn 840
Houston 799
Cambridge 625
Seattle 591
Ann Arbor 587
Wilmington 576
Beijing 563
Princeton 549
Chandler 477
Nanjing 350
Milan 333
Helsinki 326
New York 299
Dublin 297
Istanbul 292
Brescia 209
Rome 201
Chicago 180
Moscow 151
Los Angeles 149
Warsaw 141
Des Moines 127
Munich 123
Nanchang 121
The Dalles 114
San Diego 111
Hebei 105
Florence 102
Shenyang 99
Shanghai 84
Changsha 80
Salt Lake City 76
Tianjin 74
Jinan 67
London 65
Jiaxing 63
Verona 63
Turin 60
Turku 59
Trieste 57
Lancaster 56
San Francisco 54
Nuremberg 51
São Paulo 49
Hangzhou 48
Bergamo 44
Brussels 44
Dearborn 42
Bologna 39
Genoa 35
Udine 34
Romola 33
Kunming 32
Ningbo 32
Padova 32
Toronto 32
Elk Grove Village 31
Lappeenranta 29
Tampa 28
Dallas 26
Vienna 25
Falkenstein 24
Frankfurt am Main 24
Genova 24
Pisa 24
Tallinn 24
Taizhou 23
Zhengzhou 23
Brooklyn 22
Guangzhou 22
Haikou 22
Lanzhou 22
Boardman 21
Kocaeli 21
Syracuse 21
Menlo Park 20
Modena 20
Mumbai 20
Naples 19
Torino 19
Nürnberg 18
Palermo 18
Reggio Nell'emilia 18
Redwood City 17
Rozzano 17
Washington 17
Orange 16
Phoenix 16
Trento 16
Belo Horizonte 15
Miami 15
Norwalk 15
Paris 15
Rio de Janeiro 15
Bari 14
Totale 17.654
Nome #
ANTICORPI ANTI-TH/TO NELLA SCLEROSI SISTEMICA (SSC): CORRELAZIONI CLINICHE E IMMUNOLOGICHE 2.270
ANTICORPI ANTI-RNA POLIMERASI III: UN MARKER DI ESORDIO PRECOCE DI SCLEROSI SISTEMICA 1.662
Frequency Evaluation of the Interleukin-6 −174G>C Polymorphism and Homeostatic Iron Regulator (HFE) Mutations as Disease Modifiers in Patients Affected by Systemic Lupus Erythematosus and Rheumatoid Arthritis 651
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 332
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 168
Glomerular Autoimmune Multicomponents of Human Lupus Nephritis In Vivo (2): Planted Antigens. 167
Anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus patients with articular involvement: a predictive marker for erosive disease? 166
Anti-RNA polymerase III antibodies as a risk marker for early Gastric Antral Vascular Ectasia (GAVE) in systemic sclerosis 159
Prevalence and disease-specific risk factors for Lower Urinary Tract symptoms in Systemic Sclerosis: an international multi-centric study 150
Anti-RNA polymerase III antibodies: A marker of systemic sclerosis with rapid onset and skin thickening progression 149
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study 149
Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies 140
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 137
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 137
Systemic lupus erythematosus and endothelial dysfunction: A close relationship 137
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 137
Antiphospholipid antibodies mediate autoimmunity against dying cells. 135
Endothelial dysfunction in early systemic lupus erythematosus patients and controls without previous cardiovascular events 135
The limited cutaneous form of systemic sclerosis is associated with urinary incontinence: an international multicentre study 134
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 133
Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). 132
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events. 132
The clinico-serological spectrum of overlap myositis 132
C9orf72 Intermediate Alleles in Patients with Amyotrophic Lateral Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis 132
Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group 131
Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. 130
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 130
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 128
Treatment and functional outcome of patients with cystoid macular edema: a single-center experience 127
Autoimmune polyendocrine Syndromes 126
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 126
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 124
Endothelial Dysfunction In Early Systemic Lupus Erythematosus Patients And Controls Without Previous Cardiovascular Events 121
Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins 121
Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera 120
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 120
Relationship between endothelial dysfunction, videocapillaroscopy and circulating CD3+CD31+CXCR4+ lymphocytes in systemic lupus erythematosus without cardiovascular risk factors 119
Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. 118
Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. 118
Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: The positive experience of a national multicentre study 117
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 117
Evaluation of mortality, disease activity, treatment, clinical and immunological features of adult and late onset systemic Lupus erythematosus. 116
Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis 116
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 115
Aortic stiffness and left ventricular hypertrophy in rheumatoid arthritis: Comment on the article by Rudominer et al. 114
Rare autoantibodies to cellular antigens in systemic lupus erythematosus. 114
The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies. 113
Severe skin involvement in type II cryoglobulinemia successfully treated with thalidomide 111
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. 111
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 110
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women 109
Antiphospholipid syndrome and glomerular thrombosis in the absence of overt lupus nephritis 108
The role of clinically significant antiphospholipid antibodies in systemic lupus erythematosus 108
Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. 107
Pathogenetic associations of maternal anti-Ro/SSA antibodies. 107
Myositis autoantibodies and clinical phenotypes 107
[Neonatal lupus: clinical features and risk of congenital cardiac heart block in newborns from mothers with anti Ro/SSA antibodies] 107
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 106
Incidence of antiperinuclear factor in patients with psoriatic arthritis. 104
Celiac Disease Prevalence is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study 104
Anti-Ro/SSA and La/SSB antibodies 103
In vivo reflectance confocal microscopy features of cutaneous microcirculation and epidermal and dermal changes in diffuse systemic sclerosis and correlation with histological and videocapillaroscopic findings. 102
Antiperinuclear factor in psoriatic arthropathy 101
Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis 101
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. 101
Multi-antibody composition in lupus nephritis: isotype and antigen specificity make the difference 101
Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study 101
Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. 100
The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus 100
Update on Antiphospholipid Syndrome: Ten Topics in 2017 100
Cardiological features in idiopathic inflammatory myopathies. 99
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 99
Antinuclear antibodies in Frontotemporal Dementia: the tip's of autoimmunity iceberg? 99
Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. 98
International cohort study of 73 anti-Ku-positive patients: Association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis 98
Serum prealbumin is an independent predictor of mortality in systemic sclerosis outpatients 98
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 98
Elastic properties of the ascending aorta in patients with rheumatoid arthritis. 97
Autoantibodies to survival of motor neuron complex in patients with polymyositis: Immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins 97
Anti-topoisomerase-I antibodies in systemic lupus erythematosus and potential association with the presence of anti-dsDNA antibodies 97
Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. 97
Echocardiographic Evaluation of Asymptomatic Patients Affected by Rheumatoid Arthritis 95
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 95
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 95
Evaluation of Ascending Aorta Wall in Rheumatoid Arthritis by Tissue and Strain Doppler Imaging During Anti-Tumor Necrosis Factor-α Therapy 95
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 94
Switching from Intravenous to Subcutaneous Formulation of Abatacept: A Single-center Italian Experience on Efficacy and Safety 94
Serologic profile and mortality rates of scleroderma renal crisis in Italy 94
Determination of antibodies to extractable nuclear antigens by commercial kits: a multicenter study 94
Anti-carbamylated protein antibodies as a clinical response predictor in rheumatoid arthritis patients treated with abatacept 94
Predictive Features and Clinical Presentation of Interstitial Lung Disease in Inflammatory Myositis 94
Incidence of antiperinuclear factor in sera of patients with psoriatic arthritis 93
Clinical and morphological features of kidney involvement in primary Sjogren's syndrome. 92
Only monospecific anti-DFS70 antibodies aid in the exclusion of antinuclear antibody associated rheumatic diseases: an Italian experience. 92
Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. 91
Rheumatoid arthritis and diabetes mellitus: Two faces of one coin? Comment on the article by Peters et al 91
Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. 91
Neutrophil Extracellular Traps (NETs) profiles in patients with incident SLE and lupus nephritis 90
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis 89
75-SeHCAT retention test in chronic cholestatic disease: comparison with health and effect of bile acid therapy. 89
Totale 15.805
Categoria #
all - tutte 154.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 154.197


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020322 0 0 0 0 0 0 0 0 0 0 0 322
2020/20214.009 94 438 162 444 242 467 156 446 466 472 395 227
2021/20223.010 185 401 140 176 164 200 201 234 193 296 272 548
2022/20232.266 341 38 51 99 194 564 47 229 384 56 139 124
2023/20242.853 150 84 228 246 134 458 134 138 667 94 107 413
2024/20257.133 117 156 125 734 678 592 568 343 675 585 1.492 1.068
Totale 28.793